The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease

Susumu Take, Motowo Mizuno, Kuniharu Ishiki, Yasuhiro Nagahara, Tomowo Yoshida, Kenji Yokota, Keiji Oguma, Hiroyuki Okada, Yasushi Shiratori

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

OBJECTIVES: Infection with Helicobacter pylori is a risk factor for the development of gastric cancer. However, it is not known whether eradication therapy can prevent the development of gastric cancer in persons in whom the cancer is not yet established. In the present study, we investigated whether the eradication of H. pylori in patients with peptic ulcer disease reduces the likelihood of their developing gastric cancer. METHODS: Prospective posteradication evaluations were conducted in 1,342 consecutive patients (1,191 men and 151 women; mean age: 50 yr) with peptic ulcer diseases who had received H. pylori eradication therapy. After confirmation of eradication, endoscopy and a urea breath test were performed yearly. RESULTS: A total of 1,120 patients completed more than 1-yr follow-up and were followed for up to 8.6 yr (a mean of 3.4 yr). Gastric cancer developed in 8 of 944 patients cured of infection and 4 of 176 who had persistent infection (p = 0.04; log-rank test). All the gastric cancer developed in patients with gastric ulcer, but none in patients with duodenal ulcer (p = 0.005; Fisher's exact test). In patients with gastric ulcer, persistent infection was identified as a significant factor for the risk of developing gastric cancer (hazard ratio: 3.35; 95% confidence interval: 1.00-11.22; p = 0.04; Cox's proportional-hazards model). CONCLUSION: H. pylori eradication may reduce their risk of developing gastric cancer in patients with gastric ulcer. Large-scale studies in additional populations of this important international public-health issue are warranted.

Original languageEnglish
Pages (from-to)1037-1042
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume100
Issue number5
DOIs
Publication statusPublished - May 2005
Externally publishedYes

Fingerprint

Peptic Ulcer
Helicobacter pylori
Stomach Neoplasms
Stomach Ulcer
Infection
Breath Tests
Duodenal Ulcer
Proportional Hazards Models
Endoscopy
Urea
Public Health
Confidence Intervals
Therapeutics
Population
Neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. / Take, Susumu; Mizuno, Motowo; Ishiki, Kuniharu; Nagahara, Yasuhiro; Yoshida, Tomowo; Yokota, Kenji; Oguma, Keiji; Okada, Hiroyuki; Shiratori, Yasushi.

In: American Journal of Gastroenterology, Vol. 100, No. 5, 05.2005, p. 1037-1042.

Research output: Contribution to journalArticle

Take, Susumu ; Mizuno, Motowo ; Ishiki, Kuniharu ; Nagahara, Yasuhiro ; Yoshida, Tomowo ; Yokota, Kenji ; Oguma, Keiji ; Okada, Hiroyuki ; Shiratori, Yasushi. / The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. In: American Journal of Gastroenterology. 2005 ; Vol. 100, No. 5. pp. 1037-1042.
@article{6a74f738d8bf4f30ac9f6b5d99d5fa6f,
title = "The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease",
abstract = "OBJECTIVES: Infection with Helicobacter pylori is a risk factor for the development of gastric cancer. However, it is not known whether eradication therapy can prevent the development of gastric cancer in persons in whom the cancer is not yet established. In the present study, we investigated whether the eradication of H. pylori in patients with peptic ulcer disease reduces the likelihood of their developing gastric cancer. METHODS: Prospective posteradication evaluations were conducted in 1,342 consecutive patients (1,191 men and 151 women; mean age: 50 yr) with peptic ulcer diseases who had received H. pylori eradication therapy. After confirmation of eradication, endoscopy and a urea breath test were performed yearly. RESULTS: A total of 1,120 patients completed more than 1-yr follow-up and were followed for up to 8.6 yr (a mean of 3.4 yr). Gastric cancer developed in 8 of 944 patients cured of infection and 4 of 176 who had persistent infection (p = 0.04; log-rank test). All the gastric cancer developed in patients with gastric ulcer, but none in patients with duodenal ulcer (p = 0.005; Fisher's exact test). In patients with gastric ulcer, persistent infection was identified as a significant factor for the risk of developing gastric cancer (hazard ratio: 3.35; 95{\%} confidence interval: 1.00-11.22; p = 0.04; Cox's proportional-hazards model). CONCLUSION: H. pylori eradication may reduce their risk of developing gastric cancer in patients with gastric ulcer. Large-scale studies in additional populations of this important international public-health issue are warranted.",
author = "Susumu Take and Motowo Mizuno and Kuniharu Ishiki and Yasuhiro Nagahara and Tomowo Yoshida and Kenji Yokota and Keiji Oguma and Hiroyuki Okada and Yasushi Shiratori",
year = "2005",
month = "5",
doi = "10.1111/j.1572-0241.2005.41384.x",
language = "English",
volume = "100",
pages = "1037--1042",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease

AU - Take, Susumu

AU - Mizuno, Motowo

AU - Ishiki, Kuniharu

AU - Nagahara, Yasuhiro

AU - Yoshida, Tomowo

AU - Yokota, Kenji

AU - Oguma, Keiji

AU - Okada, Hiroyuki

AU - Shiratori, Yasushi

PY - 2005/5

Y1 - 2005/5

N2 - OBJECTIVES: Infection with Helicobacter pylori is a risk factor for the development of gastric cancer. However, it is not known whether eradication therapy can prevent the development of gastric cancer in persons in whom the cancer is not yet established. In the present study, we investigated whether the eradication of H. pylori in patients with peptic ulcer disease reduces the likelihood of their developing gastric cancer. METHODS: Prospective posteradication evaluations were conducted in 1,342 consecutive patients (1,191 men and 151 women; mean age: 50 yr) with peptic ulcer diseases who had received H. pylori eradication therapy. After confirmation of eradication, endoscopy and a urea breath test were performed yearly. RESULTS: A total of 1,120 patients completed more than 1-yr follow-up and were followed for up to 8.6 yr (a mean of 3.4 yr). Gastric cancer developed in 8 of 944 patients cured of infection and 4 of 176 who had persistent infection (p = 0.04; log-rank test). All the gastric cancer developed in patients with gastric ulcer, but none in patients with duodenal ulcer (p = 0.005; Fisher's exact test). In patients with gastric ulcer, persistent infection was identified as a significant factor for the risk of developing gastric cancer (hazard ratio: 3.35; 95% confidence interval: 1.00-11.22; p = 0.04; Cox's proportional-hazards model). CONCLUSION: H. pylori eradication may reduce their risk of developing gastric cancer in patients with gastric ulcer. Large-scale studies in additional populations of this important international public-health issue are warranted.

AB - OBJECTIVES: Infection with Helicobacter pylori is a risk factor for the development of gastric cancer. However, it is not known whether eradication therapy can prevent the development of gastric cancer in persons in whom the cancer is not yet established. In the present study, we investigated whether the eradication of H. pylori in patients with peptic ulcer disease reduces the likelihood of their developing gastric cancer. METHODS: Prospective posteradication evaluations were conducted in 1,342 consecutive patients (1,191 men and 151 women; mean age: 50 yr) with peptic ulcer diseases who had received H. pylori eradication therapy. After confirmation of eradication, endoscopy and a urea breath test were performed yearly. RESULTS: A total of 1,120 patients completed more than 1-yr follow-up and were followed for up to 8.6 yr (a mean of 3.4 yr). Gastric cancer developed in 8 of 944 patients cured of infection and 4 of 176 who had persistent infection (p = 0.04; log-rank test). All the gastric cancer developed in patients with gastric ulcer, but none in patients with duodenal ulcer (p = 0.005; Fisher's exact test). In patients with gastric ulcer, persistent infection was identified as a significant factor for the risk of developing gastric cancer (hazard ratio: 3.35; 95% confidence interval: 1.00-11.22; p = 0.04; Cox's proportional-hazards model). CONCLUSION: H. pylori eradication may reduce their risk of developing gastric cancer in patients with gastric ulcer. Large-scale studies in additional populations of this important international public-health issue are warranted.

UR - http://www.scopus.com/inward/record.url?scp=19144368402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19144368402&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2005.41384.x

DO - 10.1111/j.1572-0241.2005.41384.x

M3 - Article

C2 - 15842576

AN - SCOPUS:19144368402

VL - 100

SP - 1037

EP - 1042

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -